Four fledgling companies that recently joined the parade of biotechs marching to the initial public offering starting line have met with mixed investor reception.The company, which calls San Francisco home, is working on drugs for autoimmune and neurodegenerative disorders caused by an abnormal accumulation of a protein that is part of the immune system.